These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 8851384)

  • 21. Alterations in the GyrA and GyrB subunits of topoisomerase II and the ParC and ParE subunits of topoisomerase IV in ciprofloxacin-resistant clinical isolates of Pseudomonas aeruginosa.
    Lee JK; Lee YS; Park YK; Kim BS
    Int J Antimicrob Agents; 2005 Apr; 25(4):290-5. PubMed ID: 15784307
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro selected fluoroquinolone-resistant mutants of Citrobacter freundii: analysis of the quinolone resistance acquisition.
    Tavío M; Vila J; Ruiz J; Amicosante G; Franceschini N; Martín-Sánchez AM; de Anta MT
    J Antimicrob Chemother; 2000 Apr; 45(4):521-4. PubMed ID: 10747831
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of gyrA mutation and loss of OprF in the multiple antibiotic resistance phenotype of Pseudomonas aeruginosa G49.
    Pumbwe L; Everett MJ; Hancock RE; Piddock LJ
    FEMS Microbiol Lett; 1996 Sep; 143(1):25-8. PubMed ID: 8807797
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mutant prevention concentrations for single-step fluoroquinolone-resistant mutants of wild-type, efflux-positive, or ParC or GyrA mutation-containing Streptococcus pneumoniae isolates.
    Smith HJ; Walters M; Hisanaga T; Zhanel GG; Hoban DJ
    Antimicrob Agents Chemother; 2004 Oct; 48(10):3954-8. PubMed ID: 15388458
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mechanisms of high-level resistance to quinolones in urinary tract isolates of Pseudomonas aeruginosa.
    Yoshida T; Muratani T; Iyobe S; Mitsuhashi S
    Antimicrob Agents Chemother; 1994 Jul; 38(7):1466-9. PubMed ID: 7979273
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Gentamicin-induced alteration in drug susceptibility and lipopolysaccharide-composition of Pseudomonas aeruginosa isolates].
    Hasegawa M; Kobayashi I; Saika T; Nishida M
    Kansenshogaku Zasshi; 1997 Mar; 71(3):199-206. PubMed ID: 9128003
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characterization of fluoroquinolone and carbapenem susceptibilities in clinical isolates of levofloxacin-resistant Pseudomonas aeruginosa.
    Muramatsu H; Horii T; Takeshita A; Hashimoto H; Maekawa M
    Chemotherapy; 2005 May; 51(2-3):70-5. PubMed ID: 15870499
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mutant prevention concentration of ciprofloxacin and enrofloxacin against Escherichia coli, Salmonella Typhimurium and Pseudomonas aeruginosa.
    Pasquali F; Manfreda G
    Vet Microbiol; 2007 Jan; 119(2-4):304-10. PubMed ID: 16987619
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Type II topoisomerase mutations in fluoroquinolone-resistant clinical strains of Pseudomonas aeruginosa isolated in 1998 and 1999: role of target enzyme in mechanism of fluoroquinolone resistance.
    Akasaka T; Tanaka M; Yamaguchi A; Sato K
    Antimicrob Agents Chemother; 2001 Aug; 45(8):2263-8. PubMed ID: 11451683
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Purification of a 54-kilodalton protein (OprJ) produced in NfxB mutants of Pseudomonas aeruginosa and production of a monoclonal antibody specific to OprJ.
    Hosaka M; Gotoh N; Nishino T
    Antimicrob Agents Chemother; 1995 Aug; 39(8):1731-5. PubMed ID: 7486910
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Overexpression of the mexC-mexD-oprJ efflux operon in nfxB-type multidrug-resistant strains of Pseudomonas aeruginosa.
    Poole K; Gotoh N; Tsujimoto H; Zhao Q; Wada A; Yamasaki T; Neshat S; Yamagishi J; Li XZ; Nishino T
    Mol Microbiol; 1996 Aug; 21(4):713-24. PubMed ID: 8878035
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phenotypic resistance of Staphylococcus aureus, selected Enterobacteriaceae, and Pseudomonas aeruginosa after single and multiple in vitro exposures to ciprofloxacin, levofloxacin, and trovafloxacin.
    Gilbert DN; Kohlhepp SJ; Slama KA; Grunkemeier G; Lewis G; Dworkin RJ; Slaughter SE; Leggett JE
    Antimicrob Agents Chemother; 2001 Mar; 45(3):883-92. PubMed ID: 11181375
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vitro and in vivo evaluation of BO-2727 against imipenem- and/or meropenem-resistant Pseudomonas aeruginosa.
    Shibata K; Adachi Y; Kato E; Nagano R; Fuse A; Hashizume T; Ohtake N; Okamoto O; Nakagawa S
    J Antibiot (Tokyo); 1997 Feb; 50(2):135-8. PubMed ID: 9099222
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Meropenem resistance in Pseudomonas aeruginosa.
    Sumita Y; Fukasawa M
    Chemotherapy; 1996; 42(1):47-56. PubMed ID: 8751266
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of type III secretion system virulence among fluoroquinolone-susceptible and -resistant clinical isolates of Pseudomonas aeruginosa.
    Wong-Beringer A; Wiener-Kronish J; Lynch S; Flanagan J
    Clin Microbiol Infect; 2008 Apr; 14(4):330-6. PubMed ID: 18190571
    [TBL] [Abstract][Full Text] [Related]  

  • 36. nfxC-type quinolone resistance in a clinical isolate of Pseudomonas aeruginosa.
    Fukuda H; Hosaka M; Iyobe S; Gotoh N; Nishino T; Hirai K
    Antimicrob Agents Chemother; 1995 Mar; 39(3):790-2. PubMed ID: 7793896
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Fluoroquinolone and aminoglycoside resistance in chromosomal cephalosporinase-overproducing gram-negative bacilli strains with inducible beta-lactamase].
    López-Yeste M; Xercavins M; Lite J; Cuchí E; Garau J
    Enferm Infecc Microbiol Clin; 1996 Apr; 14(4):211-4. PubMed ID: 9044634
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vivo selection of Pseudomonas Aeruginosa with decreased susceptibilities to fluoroquinolones during fluoroquinolone treatment of urinary tract infection.
    Nakano M; Yasuda M; Yokoi S; Takahashi Y; Ishihara S; Deguchi T
    Urology; 2001 Jul; 58(1):125-8. PubMed ID: 11445503
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development of resistance in Pseudomonas aeruginosa to imipenem, norfloxacin, and ciprofloxacin during therapy: proof provided by typing with a DNA probe.
    Ogle JW; Reller LB; Vasil ML
    J Infect Dis; 1988 Apr; 157(4):743-8. PubMed ID: 3126247
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Multi-drug resistance of serovar E strains in clinically isolated Pseudomonas aeruginosa and analysis of genome pattern].
    Mogi T; Fukuchi K; Chen G; Wakuta R; Takagi T; Takagi Y; Gomi K
    Rinsho Byori; 1996 Feb; 44(2):147-52. PubMed ID: 8851198
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.